GSK plc

詳細情報 GSK plc 企業名

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

企業情報

企業コードGSK

会社名GSK plc

上場日May 22, 1972

設立日1999

最高経営責任者「CEO」Ms. Deborah Waterhouse

従業員数68629

証券種類Ordinary Share

決算期末May 22

本社所在地980 Great West Road

都市BRENTFORD

証券取引所London Stock Exchange

国United Kingdom

郵便番号TW8 9GS

電話番号442080475000

ウェブサイトhttps://www.gsk.com/

企業コードGSK

上場日May 22, 1972

設立日1999

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Hal V. Barron, M.D.

Non-Executive Director

647.84K

+0.04%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

483.75K

+7.69%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

36.33K

+5.89%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

2.71K

+10.51%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

1.31K

+24.45%

Dr. Harry C. (Hal) Dietz

Independent Non-Executive Director, Scientific and Medical Expert

--

Mr. James Ford

Senior Vice President, Group General Counsel, Legal and Compliance

--

Ms. Sally Jackson

Senior Vice President - Global Communications and CEO Office

--

Dr. Tony Wood, Ph.D.

Chief Scientific Officer

--

Ms. Julie Brown

Chief Financial Officer, Executive Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Hal V. Barron, M.D.

Non-Executive Director

647.84K

+0.04%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

483.75K

+7.69%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

36.33K

+5.89%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

2.71K

+10.51%

Dr. Jeannie Lee

Independent Non-Executive Director and Scientific & Medical Expert

1.31K

+24.45%

Dr. Harry C. (Hal) Dietz

Independent Non-Executive Director, Scientific and Medical Expert

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

データなし

地域別USD

会社名

収益

比率

US

4.72B

49.92%

Rest of world

2.54B

26.81%

Europe

2.20B

23.27%

事業別

地域別

データなし

株主

更新時刻: Wed, Jul 2

株主統計

種類

株主統計

比率

Dodge & Cox

3.85%

Fidelity Management & Research Company LLC

2.48%

Fisher Investments

1.47%

PRIMECAP Management Company

1.26%

JTC Employer Solutions Trusteee Ltd

0.75%

Other

90.20%

株主統計

比率

Dodge & Cox

3.85%

Fidelity Management & Research Company LLC

2.48%

Fisher Investments

1.47%

PRIMECAP Management Company

1.26%

JTC Employer Solutions Trusteee Ltd

0.75%

Other

90.20%

種類

株主統計

比率

Investment Advisor

9.26%

Investment Advisor/Hedge Fund

7.23%

Hedge Fund

0.83%

Research Firm

0.68%

Bank and Trust

0.09%

Individual Investor

0.06%

Insurance Company

0.06%

Pension Fund

0.05%

Family Office

0.02%

Other

81.72%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

1443

376.06M

18.40%

+4.22M

2025Q1

1494

378.46M

18.50%

+5.08M

2024Q4

1481

355.06M

17.14%

+27.38M

2024Q3

1472

319.97M

15.44%

-30.07M

2024Q2

1585

322.06M

15.54%

-29.11M

2024Q1

1617

318.91M

15.39%

-23.52M

2023Q4

1614

299.81M

14.57%

-35.71M

2023Q3

1570

293.92M

14.35%

-37.46M

2023Q2

1545

286.58M

13.99%

-41.88M

2023Q1

1546

281.08M

13.72%

-55.01M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Dodge & Cox

78.65M

3.85%

+10.21M

+14.92%

Mar 31, 2025

Fidelity Management & Research Company LLC

50.60M

2.48%

+6.83M

+15.61%

Mar 31, 2025

Fisher Investments

30.03M

1.47%

+11.20M

+59.43%

Mar 31, 2025

PRIMECAP Management Company

25.71M

1.26%

+446.36K

+1.77%

Mar 31, 2025

JTC Employer Solutions Trusteee Ltd

15.26M

0.75%

-5.02M

-24.75%

Mar 31, 2025

Fidelity Institutional Asset Management

9.52M

0.47%

+465.88K

+5.15%

Mar 31, 2025

Goldman Sachs Asset Management, L.P.

8.47M

0.41%

-380.46K

-4.30%

Mar 31, 2025

UBS Financial Services, Inc.

7.80M

0.38%

+1.46M

+22.95%

Mar 31, 2025

T. Rowe Price International Ltd

7.72M

0.38%

+155.40K

+2.05%

Mar 31, 2025

State Street Global Advisors (US)

6.97M

0.34%

-52.09K

-0.74%

Mar 31, 2025

詳細を見る

38.280USD

GSK plc

38.280

概要

企業名

金融